Block Timothy M, Zhou Tianlun, Anbarasan Nikhil, Gish Robert
Dr Block and Dr Zhou are professors and project leaders at the Baruch S. Blumberg Institute in Doylestown, Pennsylvania. Mr Anbarasan was affiliated with the Baruch S. Blumberg Institute at the time of this article but is now a third-year medical student affiliated with Flushing Hospital and Medical Center in Flushing, New York. Dr Gish is a professor consultant in the Department of Medicine in the Division of Gastroenterology and Hepatology at Stanford University in Stanford, California; principal of Robert G. Gish Consultants, LLC, in San Diego, California; senior medical director at St Joseph's Hospital and Medical Center in Phoenix, Arizona; and chief medical advisor of the Hepatitis B Foundation in Doylestown, Pennsylvania.
Gastroenterol Hepatol (N Y). 2016 Nov;12(11):679-689.
Is a cure for chronic hepatitis B virus (HBV) infection possible? Hepatitis C virus infection is now routinely cured medically. There is a growing expectation that new drugs for the management of chronic HBV infection should provide substantial benefit over and above that of current chronic HBV medications, if not be curative. Although the definition of medically induced cure for chronic HBV infection varies, most include sustained off-drug absence of viremia and negativity for other virologic markers. There are currently more than 29 drugs in the pipeline being tested for the management of chronic HBV infection. This article discusses the potential drugs with respect to their possible contributions to achieving medically induced cure.
慢性乙型肝炎病毒（HBV）感染有可能被治愈吗？丙型肝炎病毒感染目前在医学上已能常规治愈。人们越来越期望，用于治疗慢性HBV感染的新药即使不能治愈，也应比目前的慢性HBV药物带来更大的益处。虽然医学诱导治愈慢性HBV感染的定义各不相同，但大多数都包括停药后持续无病毒血症以及其他病毒学标志物呈阴性。目前有超过29种处于研发阶段的药物正在进行慢性HBV感染治疗的测试。本文讨论了这些潜在药物在实现医学诱导治愈方面可能做出的贡献。
